How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bcg-tokyo-172-strain-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BCG Tokyo-172 Strain Solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BCG Tokyo-172 Strain Solution (BCG Tokyo-172 Strain Solution) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine / Immunotherapeutic. Area: Oncology.

phase 3 Live attenuated vaccine / Immunotherapeutic Toll-like receptors (TLR2, TLR4); non-specific immune activation Oncology Biologic Live · refreshed every 30 min

Target snapshot

BCG Tokyo-172 Strain Solution (BCG Tokyo-172 Strain Solution) — SWOG Cancer Research Network. BCG Tokyo-172 is a live attenuated Mycobacterium bovis strain that stimulates the immune system to recognize and attack cancer cells, particularly in bladder cancer.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BCG Tokyo-172 Strain Solution TARGET	BCG Tokyo-172 Strain Solution	SWOG Cancer Research Network	phase 3	Live attenuated vaccine / Immunotherapeutic	Toll-like receptors (TLR2, TLR4); non-specific immune activation
Bacille Calmette-Guerin	Bacille Calmette-Guerin	Urological Oncology Council of Northern Tokyo	marketed	Live attenuated vaccine / Immunotherapeutic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine / Immunotherapeutic class)

SWOG Cancer Research Network · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BCG Tokyo-172 Strain Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/bcg-tokyo-172-strain-solution. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing